biote (BTMD) Competitors $4.34 -0.21 (-4.62%) Closing price 04:00 PM EasternExtended Trading$4.36 +0.02 (+0.35%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BTMD vs. NRIX, QURE, SNDX, TRVI, MENS, NAGE, XERS, NUVB, MAZE, and CRONShould you be buying biote stock or one of its competitors? The main competitors of biote include Nurix Therapeutics (NRIX), uniQure (QURE), Syndax Pharmaceuticals (SNDX), Trevi Therapeutics (TRVI), Jyong Biotech (MENS), Niagen Bioscience (NAGE), Xeris Biopharma (XERS), Nuvation Bio (NUVB), Maze Therapeutics (MAZE), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. biote vs. Its Competitors Nurix Therapeutics uniQure Syndax Pharmaceuticals Trevi Therapeutics Jyong Biotech Niagen Bioscience Xeris Biopharma Nuvation Bio Maze Therapeutics Cronos Group Nurix Therapeutics (NASDAQ:NRIX) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings. Does the media favor NRIX or BTMD? In the previous week, Nurix Therapeutics had 7 more articles in the media than biote. MarketBeat recorded 9 mentions for Nurix Therapeutics and 2 mentions for biote. Nurix Therapeutics' average media sentiment score of 1.41 beat biote's score of 0.63 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive biote 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NRIX or BTMD more profitable? biote has a net margin of 10.93% compared to Nurix Therapeutics' net margin of -234.57%. biote's return on equity of -19.44% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nurix Therapeutics-234.57% -45.26% -34.71% biote 10.93%-19.44%20.12% Which has more risk & volatility, NRIX or BTMD? Nurix Therapeutics has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, biote has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Which has higher valuation & earnings, NRIX or BTMD? biote has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNurix Therapeutics$54.55M16.65-$193.57M-$2.61-4.55biote$197.19M1.20$3.16M$0.617.11 Do insiders & institutionals believe in NRIX or BTMD? 21.7% of biote shares are owned by institutional investors. 7.4% of Nurix Therapeutics shares are owned by insiders. Comparatively, 24.0% of biote shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts recommend NRIX or BTMD? Nurix Therapeutics currently has a consensus price target of $29.31, indicating a potential upside of 146.74%. biote has a consensus price target of $8.00, indicating a potential upside of 84.33%. Given Nurix Therapeutics' higher probable upside, analysts clearly believe Nurix Therapeutics is more favorable than biote.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.82biote 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Summarybiote beats Nurix Therapeutics on 10 of the 16 factors compared between the two stocks. Get biote News Delivered to You Automatically Sign up to receive the latest news and ratings for BTMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTMD vs. The Competition Export to ExcelMetricbioteMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$248.93M$10.67B$5.63B$9.53BDividend YieldN/A1.92%4.71%4.04%P/E Ratio7.1117.8830.2020.53Price / Sales1.2029.04455.8798.78Price / Cash5.9423.1436.0158.40Price / Book-1.563.598.355.74Net Income$3.16M$234.77M$3.25B$259.12M7 Day Performance2.36%-3.28%-2.50%-3.41%1 Month Performance7.96%3.96%7.97%8.53%1 Year Performance-44.22%-14.64%34.58%15.74% biote Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTMDbiote3.2233 of 5 stars$4.34-4.6%$8.00+84.3%-43.1%$248.93M$197.19M7.11194News CoverageUpcoming EarningsNRIXNurix Therapeutics2.7493 of 5 stars$11.25+0.4%$29.31+160.6%-44.0%$857M$54.55M-4.31300Positive NewsQUREuniQure2.07 of 5 stars$14.50-3.3%$37.82+160.8%+75.3%$821.09M$27.12M-3.30500News CoverageEarnings ReportAnalyst ForecastGap UpSNDXSyndax Pharmaceuticals3.2785 of 5 stars$9.73+2.9%$34.10+250.5%-52.9%$814.01M$23.68M-2.52110News CoverageGap UpTRVITrevi Therapeutics3.7867 of 5 stars$6.82-0.6%$20.88+206.1%+139.7%$804.63MN/A-15.1620Upcoming EarningsMENSJyong BiotechN/A$11.00+4.3%N/AN/A$802.09MN/A0.0031Positive NewsQuiet Period ExpirationNAGENiagen Bioscience1.2846 of 5 stars$9.68-4.7%$13.22+36.6%N/A$800.70M$107.93M56.94120XERSXeris Biopharma3.9613 of 5 stars$5.14+0.6%$6.25+21.6%+98.4%$799.12M$203.07M-17.13290Positive NewsUpcoming EarningsNUVBNuvation Bio2.0211 of 5 stars$2.36+2.4%$7.17+204.3%-31.4%$782.60M$7.87M-1.0060Upcoming EarningsGap UpMAZEMaze TherapeuticsN/A$16.66-6.3%$23.50+41.1%N/A$778.71M$167.50M0.00121Lockup ExpirationGap UpHigh Trading VolumeCRONCronos Group1.0518 of 5 stars$2.09+4.0%N/A-15.9%$775.22M$117.61M16.08450 Related Companies and Tools Related Companies Nurix Therapeutics Alternatives uniQure Alternatives Syndax Pharmaceuticals Alternatives Trevi Therapeutics Alternatives Jyong Biotech Alternatives Niagen Bioscience Alternatives Xeris Biopharma Alternatives Nuvation Bio Alternatives Maze Therapeutics Alternatives Cronos Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTMD) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Fed Just Froze You Out (Again)The Fed’s holding rates steady—again. No clarity. No yield. No relief. But one income strategy is quietly t...Investors Alley | SponsoredSomething BIG is about to hit the stock marketMost investors won’t see it coming—but Weiss Ratings says a major market event is brewing. Their system jus...Weiss Ratings | SponsoredThe $1 Trillion Event Tesla Still Hasn’t Recovered FromIn 2010, a “Flash Crash” erased $1 trillion in minutes. Now, one trading legend says it’s happening again—insi...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
